TEMENOS
16.6.2020 09:09:06 CEST | Business Wire | Press release
Intelligence Sales League Table 2020 (SLT) . Temenos was also named a regional leader in both Europe and Americas. Temenos, with its AI and advanced cloud technology, continues to be the undisputed leader in the main product categories in the IBS League Table with the greatest number of competitors.
Temenos has been ranked as the best-selling core banking system for 15 years, as well as the best-selling vendor for digital banking for the fourth consecutive year. For 21 years running, Temenos has demonstrated consistent leadership, placing in the top two positions for core banking systems. In this year’s Sales League Table, Temenos led in nine categories, including:
- #1 Digital banking and channels with Temenos Infinity, gaining 38 new name deals
- #1 Best-selling core banking system with Temenos Transact, securing 51 new name customer deals
- #1 Retail payments system with 51 new deals for Temenos Payments
- #1 Risk management system, closing 53 new deals with Temenos Financial Crime Mitigation
- #1 Regional Leader in Europe, working with ABN AMRO and challenger banks such as Lunar and Alba
- #1 Regional Leader in Americas, partnering with innovative banks such as CWB Financial Group
- #2 Regional Leader in the Middle-East and Africa with key clients such as Egyptian National Post Organization
- #2 Regional Leader in APAC with innovative clients such as TSB with Temenos Infinity Digital Onboarding and Virgin Money Australia
- #2 Islamic Banking, partnering with the world's largest Islamic bank, Al Rajhi Bank
Max Chuard, Chief Executive Officer, Temenos, said: “It’s a great honor to be recognized as the best-selling banking software provider with the most modern technology across the main product categories of digital, core banking, retail payments, and risk management systems. Now more than ever we see an acceleration in digital and cloud adoption – banks need agile, modern banking technology across the front and back office. We offer our offer our clients, both established banks and new entrants, the winning combination of the richest banking functionality and the most advanced cloud-native, cloud-agnostic technology. We deliver solutions for the ‘New Normal’ that give our clients agility, speed to market, hyper-personalized services at the front end and automation and operational excellence in the back office. The IBS report reconfirms Temenos as global powerhouse and the world’s #1 banking software company and I would like to thank our customers, partners and employees for helping us achieve this exciting milestone.”
IBS’ Sales League Table Panel, said: “2019 was a record-breaking year for our Sales League Table, with nearly 900 validated deals globally and the highest level of vendor participation to-date. Temenos’ success was notable due to achieving #1 positions in the most intensely competitive categories including digital banking, core banking, retail payments and risk management systems. At IBS Intelligence, we are seeing banks re-visiting their digital transformation plans to support their businesses through the current COVID-19 crisis. 2020 will be an interesting year for our industry and we will be continuing to track new deals and trends to support our clients worldwide.”
Temenos continues to relentlessly focus on innovation, investing 20% of its revenue in R&D – more than any other provider in the industry. The IBS Intelligence Sales League Table is the global barometer for sales performance of banking platforms ranging from retail, to private, to Islamic, to digital-only and universal banking. The SLT provides a vital tool to executives in banks for selecting vendors for RFIs and influences vendor selection across conventional and digital banking.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005373/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom